◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SNDX

Syndax Pharmaceuticals Inc (SNDX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-13

Syndax Pharmaceuticals Inc (SNDX) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 298 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, SNDX reported $172M in revenue and ($285M) in net income.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Interactive charts & full statements → Open the SNDX valuation workbench →

SNDX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$252M	$172M	$24M	$0M	$127M	$140M	$2M	$2M	$2M	$2M	$1M	$1M	$0M	—	—	—
Gross Profit	$246M	$165M	$23M	$0M	$0M	$140M	$2M	$2M	$2M	$2M	$1M	$1M	$0M	—	—	$0M
Gross Margin %	97.6%	96.0%	96.5%	—	-0.4%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	—	—	—	—
Operating Income (EBIT)	($194M)	($273M)	($340M)	($230M)	($152M)	$26M	($71M)	($58M)	($76M)	($62M)	($44M)	($21M)	($21M)	($9M)	($9M)	($10M)
Operating Margin %	-77.0%	-158.4%	-1434.4%	—	-119.9%	18.8%	-4708.2%	-3792.9%	-5001.7%	-2939.0%	-3587.4%	-3271.6%	—	—	—	—
Net Income	($221M)	($285M)	($319M)	($209M)	($144M)	$25M	($73M)	($56M)	($74M)	($61M)	($44M)	($24M)	($20M)	($14M)	($10M)	($13M)
Net Margin %	-87.7%	-165.6%	-1346.1%	—	-113.6%	17.8%	-4816.7%	-3688.5%	-4875.5%	-2884.3%	-3645.2%	-3846.7%	—	—	—	—
EBITDA	($135M)	($252M)	($314M)	($209M)	($152M)	$26M	($71M)	($57M)	($76M)	($62M)	($44M)	($20M)	($21M)	($9M)	($5M)	($11M)
Earnings Per Share (EPS)	$-2.53	$-3.29	$-3.72	$-2.98	$-2.37	$0.48	$-1.77	$-1.84	$-2.92	$-2.90	$-3.04	$-4.31	$-2.07	$-0.20	$-0.14	$-0.00
Shares Outstanding (M)	89M	87M	86M	70M	61M	52M	41M	30M	25M	21M	15M	6M	10M	—	70M	619,958M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNDX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$73M	$65M	$68M	$46M	$38M	$20M	$8M	$12M
Gross Profit	$70M	$62M	$70M	$44M	$37M	$19M	$8M	$12M
Gross Margin %	95.6%	95.9%	102.3%	95.4%	96.6%	95.6%	100.0%	100.0%
Operating Income (EBIT)	($40M)	($34M)	($63M)	($57M)	($69M)	($84M)	($96M)	($90M)
Operating Margin %	-54.9%	-52.7%	-91.3%	-125.2%	-182.7%	-417.9%	-1254.8%	-716.6%
Net Income	($49M)	($43M)	($68M)	($61M)	($72M)	($85M)	($94M)	($84M)
Net Margin %	-67.8%	-65.8%	-99.3%	-132.4%	-189.3%	-423.3%	-1226.2%	-673.0%
EBITDA	($37M)	($31M)	($15M)	($52M)	($64M)	($84M)	($89M)	($84M)
Earnings Per Share (EPS)	$-0.55	$-0.49	$-0.79	$-0.70	$-0.83	$-0.99	$-1.10	$-0.98
Shares Outstanding (M)	89M	87M	87M	87M	86M	86M	86M	85M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNDX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($220M)	($323M)	($275M)	($161M)	($134M)	$29M	($71M)	($51M)	($69M)	($47M)	($35M)	($2M)	($14M)	($7M)	($9M)	($10M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($221M)	($323M)	($275M)	($161M)	($134M)	$29M	($71M)	($51M)	($69M)	($47M)	($35M)	($2M)	($14M)	($7M)	($9M)	($10M)
FCF Margin %	-87.7%	-187.5%	-1160.9%	—	-105.8%	20.8%	-4705.9%	-3344.8%	-4529.9%	-2251.2%	-2903.1%	-395.1%	—	—	—	—
Dividends Paid	—	—	—	—	—	—	—	—	—	—	$3M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNDX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($30M)	($50M)	($69M)	($71M)	($88M)	($95M)	($57M)	($62M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($30M)	($50M)	($70M)	($71M)	($88M)	($95M)	($57M)	($62M)
FCF Margin %	-41.6%	-77.6%	-101.6%	-154.1%	-231.3%	-474.8%	-747.2%	-498.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNDX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$704M	$530M	$725M	$613M	$497M	$450M	$301M	$64M	$84M	$137M	$109M	$90M	$13M	$17M	$2M	$5M
Cash & Cash Equivalents	$336M	$135M	$154M	$295M	$74M	$222M	$115M	$25M	$34M	$35M	$24M	$23M	$10M	$10M	$1M	$4M
Total Liabilities	$689M	$465M	$437M	$59M	$30M	$41M	$48M	$32M	$31M	$33M	$25M	$23M	$19M	$5M	$31M	$24M
Total Debt (Short + Long-Term)	$589M	$344M	$344M	$1M	$0M	$20M	$20M	$0M	$13M	$12M	$6M	$2M	$14M	$0M	$21M	$11M
Total Shareholders' Equity	$15M	$65M	$288M	$554M	$467M	$408M	$252M	$32M	$53M	$104M	$84M	$67M	($6M)	$12M	($29M)	($19M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SNDX viewer.

Other Companies in BIOTECHNOLOGY

ABSI · Absci Corp — $2 billion
TSHA · Taysha Gene Therapies Inc — $2 billion
ANAB · AnaptysBio Inc — $2 billion
INBX · Inhibrx Biosciences, Inc. — $2 billion
KARD · Kardigan, Inc. Common Stock — $2 billion
INVA · Innoviva Inc — $2 billion
BCAX · Bicara Therapeutics Inc. Common Stock — $1 billion
LTGO · Latigo Biotherapeutics, Inc. Common Stock — $1 billion

← SNDU All “S” companies SNES →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.